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Ebola Virus Disease (EVD) is the most prominent example of filovirus disease but despite being characterized
as a Category A Priority Pathogen by NIH/NIAID over a decade ago, it lacked public and private research
resources due to the absence of a commercial market. Transmission from wild animals into the human
population typically causes outbreaks of limited scale in endemic areas located in the forested regions of Central
Africa and the Philippines (for Reston ebolavirus). In the past decade, a Zaire Ebolavirus (EBOV) outbreak
causing more than 11,000 deaths in several West African countries started to reveal the true epidemic potential
that filovirus infections can have when entering an urban setting in a highly mobile society. In addition a
persistent outbreak in the Democratic Republic of the Congo has continued since August 2018 despite
significant progress with the clinical development of several EBOV vaccine candidates (one of which recently
gained regulatory approvals in Europe, the U.S. and several African countries) and the advanced testing of
promising EBOV specific therapeutics. Despite this significant progress, additional research is needed in
particular on understanding the mechanism of protection and defining immune correlates of protection for Ebola
and other filoviruses do develop fast and efficacious strategies for outbreak control as the incidence of
outbreaks and total case numbers has significantly increased over the last decades.
For our multivalent filovirus vaccine candidate, we have developed scaleable production methods using antigenspecific immunoaffinity chromatography methods to produce well-characterized lots of soluble recombinant
filovirus glycoproteins (GP) from EBOV, Marburg marburgvirus (MARV) and Sudan ebolavirus (SUDV) using
stably transformed Drosophila (S2) cells. Yields and stability of purified antigens are promising and the
immunogenicity of highly purified recombinant subunits and admixtures formulated with or without clinically
relevant adjuvants was demonstrated in mice, guinea pigs and macaques. Strong antigen-specific IgG titers as
well as virus neutralizing titers are observed after administering two or three doses of adjuvanted formulations.
Since being able to demonstrate that both humoral and cell-mediated immunity are elicited by recombinant GP
and protection has been demonstrated in rodents, our formulation development is mainly driven by
immunogenicity and efficacy testing in non-human primates.
Recent challenge studies using the “gold-standard” cynomolgus macaque models demonstrate that vaccination
with formulations of recombinant EBOV, MARV or SUDV subunits and an emulsion-based adjuvant consistently
produce high anti-EBOV IgG and virus neutralizing titers. Such vaccination prevents viremia subsequent to live
virus challenge with the homologous live virus and protects animals from terminal filoviral disease. Most
importantly, we also demonstrated promising durability of protection of our monovalent EBOV vaccine
candidate. Currently ongoing work being discussed focuses on the development of bi- and trivalent vaccine
formulations and the testing of thermostable formulations containing recombinant subunits as well as the
adjuvant in a single vial.
Our results demonstrate that formulations based on insect cell expressed subunit can be used to produce
thermostable, multivalent and durable vaccines for protection against high-consequence pathogens which are
highly immunogenic in multiple animal species and are capable of providing effective vaccine protection against
live virus challenge.
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